Combined Insulin‐tolbutamide Therapy in the Management of Insulin‐dependent Diabetes

Fabrykant, Maximilian; Ashe, Benjamin I.

doi:10.1111/j.1749-6632.1959.tb44937.x

Cited by 15 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Occasional reports had indicated, years ago, that SUs can be of benefit, when given together with insulin to patients with labile diabetes (Fabrykant 1959): unfortunately, none of the patients were clearly characterized and we can not exclude that in these patients the SUs employed were active by stimulating endogenous insulin release. More recently (Lebovitz et al 1977), it has been shown that in type 2 diabetes SUs can enhance the hypoglycemic effect of acute IV insulin injection but the study was not apt to indicate or to exclude an additional effect of SUs on endogenous insulin release.…”

Section: Discussionmentioning

confidence: 89%

Sulfonylureas Enhance In Vivo the Effectiveness of Insulin in Type 1 (Insulin Dependent) Diabetes Mellitus

et al. 2008

View full text Add to dashboard Cite

Indirect evidence suggests that sulfonylureas, in addition to stimulating insulin release, exert additional effects at extrapancreatic levels which are of value in the management of type 2 diabetes. In order to characterize in vivo some of these effects, insulin sensitivity was studied in 9 type 1 diabetics with no residual insulin secretory activity, during treatment with chlorpropamide (250 mg b.i.d. for 8 days) and with glipizide (5 mg t.i.d. for 8 days). Employing the glucose clamp technique with the aid of an artificial pancreas (Biostator), glucose disposal during insulin infusion (0.1 U/kg in 60 min) was calculated by the amount of glucose required to keep the blood glucose at preinfusion levels. Chlorpropamide and glipizide administration was accompanied by a significant increase of the amount of glucose required to clamp blood glucose levels, while serum (free) insulin levels were superimposable during the different clamping studies. In the absence of endogenous insulin release, these data strongly suggest that the two sulfonylureas employed enhance in vivo the peripheral sensitivity to insulin. Further studies are required to indicate a preferential site of action (liver, muscle, adipose tissue) of sulfonylureas.

show abstract

Section: Discussionmentioning

confidence: 89%